Rapid review shows rSIFN-co therapy improves outcomes in COVID-19, suggesting better efficacy than traditional interferon.
This study aims to see how effective interferon nebulization therapy is in COVID-19 patients. The method used is rapid review. The results of the study showed that rSIFN-co therapy has advantages, namely the duration of faster clinical improvement, the time for negative conversion of viral nucleic acid on mechanical ventilation is also shorter. While interferon-alpha therapy itself, because it still uses traditional principles, clinical improvement that occurs is a little slow. Conclusion, the use of interferon-alpha is less effective for the treatment of COVID-19 than the use of rSIFN-co therapy.
No takes yet. Share an insight, caveat, or question.
Rositianti et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: